Menu Close

Funding Opportunities

 FUNDING OPPORTUNITIES

DoD Lung Cancer, Idea Development Award

Purpose: The FY21 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field
Amount: $350,000 over 2 years

Pre-Application Deadline: 05 May 2021

 

Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) entitled “Innovative Research in Cancer Nanotechnology (IRCN)” encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $450,000/yr for 5 years

Deadline: 06 May 2021

 

Paul Marks Prize for Cancer Research

Purpose: The Paul Marks Prize for Cancer Research recognizes a new generation of leaders in cancer research who are making significant contributions to the understanding of cancer or are improving the treatment of the disease through basic or clinical research. The prize is intended to encourage young investigators (age 50 or younger) who have a unique opportunity to help shape the future of cancer research.

Funder: Memorial Sloan Kettering Cancer Center
Applicant:
 Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000 – $150,000

Deadline: 07 May 2021

 

DoD Peer Reviewed Medical Research Program Focused Program Award

Purpose: The PRMRP Focused Program Award is intended to optimize research and accelerate solutions through a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal. Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $7,200,000 over 4 years

Pre-Application Deadline: 13 May 2021

 

DoD Peer Reviewed Cancer Research Program Idea Award

Purpose: The FY21 PRCRP Idea Award supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research that are relevant to active-duty Service Members, Veterans, other military beneficiaries, and the American public. The Idea Award is not intended to support a logical progression of an already established research project. The proposed research should be innovative, and may introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $500,000 over 3 years

Pre-Application Deadline: 20 May 2021

 

DoD Peer Reviewed Cancer Research Program Impact Award

Purpose: The FY21 PRCRP Impact Award supports hypothesis-driven, high-impact research. The Impact Award mechanism encourages applications with mature research projects that specifically focus on critical scientific or clinical cancer issues, which, if successfully addressed, have the potential to make a major near-term impact on at least one of the FY21 PRCRP Topic Areas. Important factors under consideration will be continuity of research, clinical applicability, and leveraging of clinical samples and trials. Through the Impact Award, the PRCRP seeks to build foundations in underfunded, understudied, and/or lethal militarily relevant cancer or research areas. The Impact Award supports identifying scientific outcomes through rigorous, robust research that are translatable toward treatment and/or preventive strategies. Research proposed should aim to accelerate promising findings toward clinical applicability and leverage research results to maximize impact.

Funder: Department of Defense (DoD)
Applicant: Mid-Career to Established in Field
Amount: $1,250,000 over 3 years

Pre-Application Deadline: 20 May 2021

 

Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA), entitled “Toward Translation of Cancer Nanotechnology Interventions (TTNCI)” is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The “Toward Translation of Nanotechnology Cancer Interventions” (TTNCI) awards are designed to mature experimental nanomedicines relying on “next-generation” nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $475,000/yr for 4 years

Deadline: 20 May 2021

 

Graduate Research Training Initiative for Student Enhancement (G-RISE) (T32)

The goal of the Graduate Research Initiative for Student Enhancement (G-RISE) program is to develop a diverse pool of scientists earning a Ph.D., who have the skills to successfully transition into careers in the biomedical research workforce. This funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

Funder: National Institutes of Health (NIH)

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field

Amount: $25,000 – $1,000,000

Deadline: 21 May 2021

 

National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

Purpose: With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective. 

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 25 May 2021

 

Cancer Research Education Grants Program – Courses for Skills Development (R25 Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000/yr for up to 5 years

Deadline: 25 May 2021

 

Cancer Research Education Grants Program – Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $150,000/yr for up to 2 years

Deadline: 25 May 2021

 

Cancer Research Education Grants Program – Research Experiences (R25 Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000/yr for up to 5 years

Deadline: 25 May 2021

 

Genomic Community Resources (U24 Clinical Trial Not Allowed)

Purpose: To facilitate genomic research and the dissemination of its products, NHGRI supports genomic resources that are crucial for basic research, disease studies, model organism studies, and other biomedical research. Awards under this FOA will support the development and distribution of genomic resources that use cost-effective approaches and will be valuable for the broad research community. Such resources include (but are not limited to) databases and informatics resources (such as human and model organism databases, ontologies, and analysis toolsets), comprehensive identification and collections of genomic features (such as functional genomic elements), and standard data types produced using central sets of samples (such as structural variants in 1000 Genomes or GTEx samples).

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 25 May 2021

 

Maximizing Access to Research Careers (T34)

Purpose: The goal of the Maximizing Access to Research Careers (MARC) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 26 May 2021

Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)

Purpose: The goal of the Undergraduate Research Training Initiative for Student Enhancement (U-RISE) program is to develop a diverse pool of undergraduates who complete their baccalaureate degree, and transition into and complete biomedical, research-focused higher degree programs (e.g., Ph.D. or M.D./Ph.D.). This funding opportunity announcement (FOA) provides support to eligible, domestic institutions to develop and implement effective, evidence-informed approaches to biomedical training and mentoring that will keep pace with the rapid evolution of the research enterprise. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring, and career development elements to prepare trainees for the completion of research-focused higher degree programs in biomedical fields

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 26 May 2021

 

Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)

Purpose: The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 26 May 2021

 

Neural Regulation of Cancer (R21 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) encourages collaborative, transdisciplinary research with both neuroscience and cancer research elements, which together will advance our current understanding of the nervous system’s contribution to cancer. Leveraging the knowledge, tools, experimental models and reagents in neuroscience research to uncover novel mechanisms used by the nervous system to promote tumor initiation, progression and metastasis can ultimately inform key areas of cancer research including the prevention and treatment of non-central nervous system tumors.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 27 May 2021

 

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $400,000 over 3 years

Deadline: 27 May 2021

 

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $400,000 over 3 years

Deadline: 27 May 2021

 

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: 300,000/yr for 3 years

Deadline: 27 May 2021

 

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: 300,000/yr for 3 years

Deadline: 27 May 2021

 

Metastasis Research Network (U54 Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to develop a comprehensive and cohesive understanding of cancer metastasis. Towards this goal, the National Cancer Institute (NCI) will support several U54 Specialized Centers that together will form the Metastasis Research Network (MetNet). Each MetNet Center should propose an overarching scientific theme that will be pursued through two or three scientific inter- and multi-disciplinary basic research projects. The projects should use integrative approaches to elucidate and integrate a mechanistic understanding of the non-linear, dynamic, and emergent processes in metastasis. Overarching themes should encompass the interplay between at least two central elements in the metastatic process such as early dissemination, cellular and/or physical microenvironment crosstalk, dormancy, or mechanisms of responses by metastatic cells to therapies.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,200,000 over 5 years

Deadline: 28 May 2021

 

Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Allowed)
Purpose: The Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions initiative is soliciting applications to support collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in developing, implementing, or disseminating innovative and effective interventions to prevent, reduce, or eliminate health disparities and advance health equity. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in addressing health disparities and advancing health equity.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 28 May 2021

 

Improving Methods for Conducting Patient-Centered Outcomes Research

Purpose: With this PCORI Funding Announcement (PFA), PCORI aims to fund studies that address high-priority methodological gaps in patient-centered outcomes research (PCOR) and clinical comparative effectiveness research (CER). PCORI seeks to improve how massive amounts of data from a variety of sources can be: (1) appropriately analyzed and integrated into clinical care and health care delivery systems, and (2) facilitate population health models and social determinants of health analyses. Proposals should address mechanisms seeking to improve equitable, inclusive data collection and aggregation.

Funder: Patient-Centered Outcomes Research Institute (PCORI)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $750,000 over 3 years

Letter of Intent Deadline: 29 May 2021

 

Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed)

Purpose: The Basic Instrumentation Grant (BIG) Program encourages applications from groups of NIH-supported investigators to purchase a single high-priced, specialized, commercially available instrument or an integrated instrumentation system. The BIG Program is limited to institutions that have not received S10 instrumentation funding of $250,001 or greater in any of the Federal fiscal years 2018-2020. Instruments supported include, but are not limited to, basic cell sorters, confocal microscopes, ultramicrotomes, gel imagers, or computer systems.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $25,000 – $250,000

Deadline: 01 Jun 2021

 

Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)

Purpose: The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. Instruments supported include, but are not limited to: X-ray diffractometers, mass spectrometers, nuclear magnetic resonance spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000 – $600,000

Deadline: 01 Jun 2021

 

High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)

Purpose: The High-End Instrumentation (HEI) Grant program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. Instruments supported include, but are not limited to, biomedical imagers, high throughput robotic screening systems, X-ray diffractometers, mass spectrometers, nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, and cell sorters.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $600,001 – $2,000,000

Deadline: 01 Jun 2021

 

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications).

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $475,000/yr for 5 years

Deadline: 02 Jun 2021

 

The Role of Epitranscriptomics in Development and Disease (R01 – Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $499,999/yr for up to 5 years

Deadline: 03 Jun 2021

 

Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 – Independent Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on courses for skills development

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $200,000/yr for 4 years

Deadline: 04 Jun 2021

 

Addressing Health Disparities among Immigrant Populations through Effective Interventions (R01 Clinical Trial Optional)

Purpose: The purpose of the Immigrant health initiative is to support research to design and implement effective interventions to enhance health advantages and reduce health disparities among U.S. immigrant populations (particularly migrant workers, recent and 1st generation immigrants) and address factors related to immigration experiences that affect health. For the purposes of this funding announcement, the term “1st generation” refers to people who were born in their native country and relocated to the U.S. The term “2nd generation” refers to the U.S. born children of 1st generation immigrants.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

Purpose: Through this funding opportunity announcement (FOA), NCI wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes (NIDCD, NIMH); and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set; and 4) hit-to-lead optimization.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Advancing Research to Develop Improved Measures and Methods for Understanding Multimorbidity (R01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs.

Funder: National Institutes of Health (NIH)

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum. The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) encourages research projects that focus on innovative research in the isolation and characterization of extracellular vesicles (EVs) and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of EVs as well as the computational analysis of the cargo carried in these vesicles.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

Purpose: The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of project

Deadline: 05 Jun 2021

 

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Purpose: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. The special Interest is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)

Purpose: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) along with the National Human Genome Research Institute (NHGRI) and National Institute of Dental and Craniofacial Research (NIDCR) encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer genomic and epidemiology by supporting the analysis of existing genetic or genomic datasets, in combination with other omics and environmental, clinical, behavioral, lifestyle, and molecular profiles data. Applicants are encouraged to leverage existing genetic data and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in genomic and epidemiology cancer research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $350,000/yr for 5 years

Deadline: 05 Jun 2021

 

Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations (R01 Clinical trial not allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Jun 2021

 

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. Collaborative, multidisciplinary projects that engage the fields of regenerative medicine, tissue engineering, biomaterials, and bioengineering with cancer biology will be essential for generating novel experimental models that mimic cancer pathophysiology in the context of a testable cancer research hypothesis. The projects supported by this FOA will collectively participate in the Cancer Tissue Engineering Collaborative (TEC) Research Program. The Cancer TEC Program will (1) catalyze the advancement of innovative, well characterized in vitro and ex vivo systems available for cancer research, (2) expand the breadth of these systems to several cancer types, and (3) promote the exploration of cancer phenomena with biomimetic tissue-engineered systems.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $400,000/yr for 5 years

Deadline: 05 Jun 2021

 

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve several stages of the cancer continuum and any phase of the translational spectrum.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 05 Jun 2021

 

New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)

Purpose: The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 06 Jun 2021

 

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 08 Jun 2021

 

Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000 over 3 years

Deadline: 08 Jun 2021

 

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $600,000/yr for 5 years

Deadline: 08 Jun 2021

 

Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional)   

Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 09 Jun 2021

 

Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)

Purpose: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) announces its interest in supporting meritorious research projects in three distinct domains related to cancer communication: 1) the utility and application of new cancer communication surveillance approaches; 2) the development and testing of rapid cancer communication pilot interventions using innovative methods and designs; and 3) the development and testing of multilevel cancer communication models emphasizing bidirectional influence between levels. For such projects, applicants should apply communication science approaches to the investigation of behavioral targets and health outcomes related to cancer prevention and control. Applications should utilize one or more innovative communication research methodologies. The R21 activity code is intended to encourage new exploratory and developmental research projects.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 09 Jun 2021

 

Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses.  Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation. 

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 10 Jun 2021

 

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

Purpose: The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and “protected time” for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 12 Jun 2021

 

Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. This FOA uses the R21 mechanism. The R21 activity code is intended to encourage new exploratory and developmental research projects.
Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 16 Jun 2021

 

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000/yr for 2 years

Deadline: 16 Jun 2021

 

NIMHD Exploratory/Developmental Research Grant Program (R21 – Clinical Trial Optional)

Purpose: NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. The R21 activity code is intended to encourage new exploratory and developmental research projects.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 16 Jun 2021

 

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

Purpose: The purpose of this funding opportunity announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 16 Jun 2021

 

Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 – Clinical Trial Optional)

Purpose: The Agency for Healthcare Research and Quality’s (AHRQ) mission is to produce evidence to make health care safer, of higher quality, more accessible, equitable, and affordable, and to work within the U.S. Department of Health and Human Services and with other partners to make sure that the evidence is understood and used. This FOA invites applications that propose research projects that test promising digital healthcare interventions aimed at improving quality of care and healthcare services delivery at the point of care. This FOA will use the Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities, and up to 3 years of R33 support for expanded activities.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 16 Jun 2021

 

Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)

Purpose: Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000/yr for 2 years

Deadline: 16 Jun 2021

 

Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods.  Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 17 Jun 2021

 

Enhancing Science, Technology, EnginEering, and Math Educational Diversity (ESTEEMED) Research Education Experiences (R25)

Purpose: The NIH Research Education Program (R25) supports research educational activities that complement other formal training programs in the mission areas of the NIH Institutes and Centers. The overarching goals of the NIH R25 program are to: (1) complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs; (2) encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research; (3) help recruit individuals with specific specialty or disciplinary backgrounds to research careers in biomedical, behavioral and clinical sciences; and (4) foster a better understanding of biomedical, behavioral and clinical research and its implications. The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 24 Jun 2021

 

NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)

Purpose: This funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000 over 2 years

Deadline: 24 Jun 2021

 

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

Purpose: The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation’s research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation’s biomedical and behavioral research effort.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000 over 3 years

Deadline: 25 Jun 2021

 

Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)

Purpose: The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at these applicant institutions. Eligible institutions must award baccalaureate science degrees, and have received less than 6 million dollars per year of NIH support (total costs) in 4 of the last 7 fiscal years.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000 over 3 years

Deadline: 25 Jun 2021

 

Damon Runyon-Rachleff Innovation Award

Purpose: The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.

Funder: Damon Runyon Cancer Research Foundation
Applicant: Early Career and Emerging in Field
Amount: $200,000/yr for 4 years

Deadline: 01 Jul 2021

 

Innovative Basic Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Not Allowed)

Purpose: The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 08 Jul 2021

 

Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)

Purpose: The overall objective of this exploratory/developmental grant Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 08 Jul 2021

 

Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)

Purpose: The National Cancer Institute’s (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $400,000/yr for 5 years

Deadline: 09 Jul 2021

 

Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggressive Cancer (R01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) will support the development of state-of-the-art projects that include imaging, biomarkers, digital pathomic and other -omic integration strategies for improving current approaches for the earliest detection of premetastatic aggressive cancer as well as identifying precancerous lesions that will subsequently demonstrate an aggressive phenotype. This FOA specifically attempts to address and improve diagnostic uncertainty in clinical decisions in a technology agnostic manner by improving sensitivity and specificity of applied tests. N-dimensional co-registered, cross-correlated imaging results integrated with multiplexed biomarker data and digital pathomics using analytic strategies such as artificial intelligence and virtual reality visualization for improving discovery are encouraged. The projects supported by this FOA will collectively participate in the existing Consortium for Imaging and Biomarkers (CIB) Research Program. The goals of the CIB are to: (1) improve diagnostic performance by developing methodology for the early identification of lethal cancer versus non-lethal disease, (2) to minimize/better manage overdiagnosis and (3) to reduce false positives and false negatives.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 09 Jul 2021

 

DoD Prostate Cancer Research Program Data Science Award

Purpose: The FY21 PCRP Data Science Award mechanism supports research where quantitative and analytical approaches, processes, and/or systems are developed and/or used to obtain knowledge and insight from large and/or complex sets of prostate cancer data. If successful, the studies will enable progress towards addressing one or more of the FY21 PCRP Overarching Challenges. This mechanism is intended to fund research built upon the logic, concepts, and methods of the PCRP research areas as they pertain to prostate cancer.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,000,000 over 3 years

Pre-Application Deadline: 15 Jul 2021

 

DoD Prostate Cancer Research Program Health Equity Research and Outcomes Improvement Consortium Award

Purpose: The FY21 PCRP Health Equity Research and Outcomes Improvement Consortium (HEROIC) Award supports a synergistic, multi-institutional collaboration incorporating innovative and translational approaches that have the potential to make a major impact on specific FY21 PCRP Overarching Challenges. All applications are required to address one or both of the following FY21 PCRP Overarching Challenges: Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer and/or Advance Health Equity and Reduce Disparities in Prostate Cancer.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $2,700,000 over 2 years

Pre-Application Deadline: 15 Jul 2021

 

Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)

Purpose: The overarching goal of this funding opportunity announcement (FOA) for the Common Fund program “Illuminating the Druggable Genome” is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the IDG consortium’s Knowledge Management Center (KMC) as well as the broader IDG Consortium. Awards will support the IDG Consortium by: (1) developing and deploying tools to enhance the community’s ability to process, analyze, and visualize IDG data, (2) prioritizing new data resources and methods to be incorporated into Pharos that will strengthen predictions about physiological and disease associations around IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels), and (3) developing methods to prioritize IDG-eligible understudied proteins for deeper study using experimental assays both developed within the IDG pipeline or by the larger community.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000 over 2 years

Deadline: 15 Jul 2021

 

DoD Peer Reviewed Cancer Research Program Behavioral Health Science Award

Purpose: The Behavioral Health Science Award supports innovative research and high-reward studies that span the spectrum of behavioral health science, including quality of life, symptom management, resilience, neurocognitive deficits, and psychosocial issues related to cancer diagnosis, treatment, and survivorship. Studies must address one or more of these critical issues in at least one of the FY21 PRCRP Topic Areas. The overall goal of the Behavioral Health Science Award is to advance behavioral health cancer science and fill gaps in the understanding of survivorship, including investigations into the psychological health and well-being of those affected by cancer (e.g., patients, family members).

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,000,000 over 4 years

Pre-Application Deadline: 29 Jul 2021

 

DoD Peer Reviewed Cancer Research Program Career Development Award

Purpose: The PRCRP is seeking to advance cancer research through development of early-career investigators. Depending on the accomplishments of the candidates, the PRCRP offers two distinct early-career development options for the Career Development Award:  the Fellow Option and the Virtual Cancer Center Scholar Option. The FY21 Career Development Award – Fellow Option supports independent, early-career investigators (referred to as Fellows) to conduct impactful research with the guidance of an experienced cancer researcher (i.e., Career Guide) and presents an opportunity for Fellows to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of cancer research.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field
Amount: $400,000 over 3 years

Pre-Application Deadline: 29 Jul 2021

 

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 11 Aug 2021

 

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Purpose: The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the NIH’s mission and to the public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge, whether or not a published report results from such meeting. The NIH recognizes the value to members of the research community and all other interested parties in supporting such forums.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 12 Aug 2021

 

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)

Purpose: This initiative will support (1) observational research to understand the role of structural racism and discrimination (SRD) in causing and sustaining health disparities, and (2) intervention research that addresses SRD in order to improve minority health or reduce health disparities.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $500,000/yr for 5 years

Deadline: 24 Aug 2021

 

DoD Prostate Cancer Research Program Clinical Consortium Award

Purpose: The mission of the FY21 PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being. Applications should aim to understand the impact of prostate cancer on quality of life for the cancer survivor, their family, caregivers, and their community with the goal of improving and enhancing quality of life and overall health and wellness.  Studies should consider both short- and long-term quality of life outcomes.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,200,000 – $7,200,000

Pre-Application Deadline: 09 Sept 2021

 

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and/or clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on 1) mechanistic studies with translational endpoints; and/or 2) longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.  

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 20 Sep 2021

 

National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

Purpose: With this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective. 

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 25 Sep 2021

 

Cancer Research Education Grants Program – Courses for Skills Development (R25 Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000/yr for up to 5 years

Deadline: 25 Sep 2021

 

Cancer Research Education Grants Program – Curriculum or Methods Development (R25 Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $150,000/yr for up to 2 years

Deadline: 25 Sep 2021

 

Cancer Research Education Grants Program – Research Experiences (R25 Clinical Trial Not Allowed)

Purpose: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients, in order to advance the NCI mission.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000/yr for up to 5 years

Deadline: 25 Sep 2021

 

Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 – Clinical Trial Not Allowed)

Purpose: SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031) with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions. The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $125,000/yr for 4 years

Deadline: 28 Sep 2021

 

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $400,000 over 3 years

Deadline: 29 Sep 2021

 

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection, and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $400,000 over 3 years

Deadline: 29 Sep 2021

 

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) invites grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: 300,000/yr for 3 years

Deadline: 29 Sep 2021

 

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-

 

 

relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: 300,000/yr for 3 years

Deadline: 29 Sep 2021

 

Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) – Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute’s (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 08 Oct 2021

 

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Purpose: This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research. Research areas of interest include but are not limited to research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $250,000/yr for 5 years

Deadline: 08 Nov 2021

OPEN DEADLINES

The Lewin Fund Science Grant

Purpose: The Lewin Fund invites novel laboratory research proposals and clinical investigations pertaining to the fundamental questions broadly related to women’s cancer: Tumor biology, novel molecular targets, companion diagnostics, and hereditary genetics.

Funder: The Lewin Fund
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: Open | LOI Required

A Kids’ Brain Tumor Cure (AKBTC) Research Grant

Purpose: A Kids’ Brain Tumor Cure, a national non-profit organization, was founded in 2007 by a group of dedicated parents, physicians, and friends to improve the treatment, quality of life, and long-term outlook for children with brain tumors through research, support, education, and advocacy. The number one priority of A Kids’ Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low-grade glioma brain tumor research and to award research grants for the most promising programs and studies. Our hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children’s brain tumors. Proposals related to basic and translational projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

Funder: Pediatric Low-Grade Astrocytoma Foundation (PLGA)
Applicant: Early Career and Emerging in Field
Amount: varies

Deadline: open

SWOG Trial Support (STrS)

Purpose: SWOG Trial Support (STrS) is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support qualified trial components that occur during the time of patient enrollment to avoid delay of trial activation or, in some cases, to ensure real-time collection of additional critical data. Qualifying trial components may include those that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, provision of materials to trial sites, or PROs. In most instances, qualifying applications will fund core trial components or integral biomarkers and TM-related work. However, to further support critically important TM that is not funded by industry, and that has been previously submitted and denied to BIQSFP, the review committee will consider funding integrated biomarkers. Integrated biomarkers that are included for support under this mechanism must be highly likely to inform future SWOG protocols, demonstrating strong potential to ultimately impact SWOG patients. STrS funding is not intended for salary support of Principal Investigators or Co-PIs.
Funder: The Hope Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $75,000/year over 1 or 2 years

Deadline: open

Research Consultation Awards

Purpose: The EMDR Research Foundation invites applications for its research consultation awards. These aim to facilitate access to expertise that would advance the development of a research project that focuses on eye movement desensitization and reprocessing therapy, to support the completion of such projects, or the writing of an article on the topic for publication in a professional journal. Research priority areas include the use of eye desensitization and reprocessing therapy to treat anxiety; depression; military post-traumatic stress disorder; phantom limb pain; or to enhance the recovery from cardiac events and cancer diagnosis and treatment. Projects may also focus on the use of eye desensitization and reprocessing therapy in diagnostic categories including addictions, eating disorders, dissociative disorders, additional medical or somatic conditions and suicide impact or prevention.

Funder: EMDR Research Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field / Graduate Student
Amount: $1,000

Deadline: open

Drug Screening Program RFP

Purpose: The chordoma research community continues to expand its knowledge about the biology of the disease and identify new targets that may be important in regulating tumor cell growth and/or progression. In many cases, repurposed drugs from other indications directed against these targets exist that could be rapidly tested for effects on chordoma cell growth. In addition, as with many other cancers, the need for rationally designed combination approaches have to be explored for their ability to more effectively inhibit chordoma growth and potentially induce cell killing. To support these needs and complement the existing in vivo program, the Foundation is now offering a new in vitro drug screening service to rapidly assess new drugs and combination approaches. Nominated drugs can be tested for their effects on chordoma cell viability in a number of validated cell lines in a rapid and efficient manner through a centralized laboratory. Additional assay formats including cell killing and mechanistic readouts will be considered.
Funder: Chordoma Foundation

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $10,000

Deadline: open

Research Grants

Purpose: The Fanconi Anemia Research Fund (FARF) seeks to fund interdisciplinary and translational research efforts that will lead to rapid discovery and development of therapies or strategies that treat, control, or cure Fanconi anemia (FA). The top priority is to define the pathogenesis of cancers including head and neck and anogenital squamous cell carcinomas that affect persons with FA, and to develop strategies for early detection, prevention, treatment, and cure. Projects may be pre-clinical or clinical in nature. Preliminary data is not required but is preferred. FARF seeks to fund innovative project ideas that have the potential to make significant impact on our understanding of the disease and clinical care for people with FA.

Funder: Fanconi Anemia Research Fund
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $25,000 – $250,000 over 1 or 2 years

Deadline: open

TRAVEL GRANTS AND FELLOWSHIPS

ASCO Resident Travel Award for Underrepresented Populations (RTA)

Purpose: The Resident Travel Award (RTA) provides financial support for residents from underrepresented populations to attend the ASCO Annual Meeting. This award allows physician residents interested in a career in oncology to travel to the ASCO Annual Meeting, where they will have the opportunity to meet oncologists and to learn more about career option in the field of oncology.

Funder: American Society of Clinical Oncology (ASCO) | Conquer Cancer Foundation
Applicant: Early Career and Emerging in Field / Minority
Amount: $1,500

Deadline: 12 Nov 2020

Conferences and Workshops

Purpose: The sponsor is seeking applications for researcher-led scientific conferences and workshops that will facilitate: collaboration between members of the research community; Discussion between interdisciplinary researchers or healthcare workers; New partnerships between research and industry; The identification of key barriers which need to be overcome if we are to progress research in this field; A focus on improving quality of life. All applications must address at least one of the priorities highlighted in the Charity Strategy ‘Defeating Brain Tumours’. Applications that do not fit the strategic priorities of The Charity will not be funded.

Funder: Brain Tumour Charity
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: £5,000

Deadline: open

ANTICIPATED OPPORTUNITIES

Department of Defense Breast Cancer Research Program

The Department of Defense Breast Cancer Research Program is anticipated to provide funding to the Department of Defense BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.

Funder: Department of Defense
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $450,000 – $25,000,000

Deadline: forthcoming

PAST DUE OPPORTUNITIES

Centers to Advance Research in Endometriosis (CARE) (P01 Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support the novel development of Centers to Advance Research in Endometriosis (CARE). These multidisciplinary programs will incorporate basic, translational, and/or clinical studies (excluding clinical trials) in a collaborative entity to accelerate research advances through sharing of knowledge and resources. The ultimate goal of the program is to improve female reproductive health through successful prevention and treatment of endometriosis.
Funder: Marsha Rivkin Center for Ovarian Cancer Research
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $3,800,000

Letter of Intent Deadline: 30 Oct 2020

AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship

Purpose: The AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship encourages and supports postdoctoral or clinical research fellows to establish a successful career path in cancer research. Research proposed for funding may be in any area of basic cancer research. This fellowship provides a two-year grant of $120,000 to support the salary and benefits of the fellow while working on a mentored basic cancer research project. A partial amount of funds may be designated for non-personnel expenses, such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.
Applicant: Early Career and Emerging in Field
Amount: $120,000 over two years

Letter of Intent Deadline: 30 Oct 2020

Special Opportunity: St. Baldrick’s Foundation-MRA Young Investigator Award in Pediatric Melanoma

Purpose: Although multi-institutional studies and patient registries have improved our understanding of pediatric melanoma in recent years, a complete understanding of this disease, as well as how best to diagnose and treat pediatric melanoma patients remains a critical unmet need. The MRA is pleased to partner with St. Baldrick’s Foundation to offer a special opportunity to support research to improve the diagnosis, understanding, and treatment of pediatric melanoma.

Funder: Melanoma Research Alliance (MRA)
Applicant: Early Career and Emerging in Field
Amount: $225,000 over 3 years

Eligibility Checklist Due: 21 Oct 2020

Deadline: 4 Nov 2020

Clinic and Laboratory Integration Program (CLIP) Grants

Purpose: The Cancer Research Institute established Clinic and Laboratory Integration Program to support investigators who are studying critical topics at the intersection of laboratory and clinical research in immuno-oncology. CLIP Grants provide funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The grant will support pre-clinical and translational research, which will provide information that can be directly applied to optimizing cancer immunotherapy in the clinic. Proposals in all cancers are encouraged.
Funder: Cancer Research Institute Clinic and Laboratory Integration Program | Chordoma Foundation

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $200,000 over two years

Letter of Intent Deadline: 01 Nov 2020

Deadline: 01 Feb 2021

Annual DeGregorio Foundation Award for Cancers of the Esophagus and Stomach

Purpose: Research projects are selected through a rigorous review process, and project goals must align with The DeGregorio Family Foundation’s mission. The Foundation’s application review process is guided by its Scientific Advisory Board. Criteria for successful grants are impact, likelihood of completion and making a significant contribution to understanding, diagnosis, or treating gastric or esophageal malignancies. The intention of this award is to provide seed funding for research in upper GI malignancies. Funded applicants are expected to apply for subsequent peer-reviewed support (i.e. NIH or similar agency).

Funder: DeGregorio Family Foundation for Stomach and Esophageal Cancer Research and Education
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $250,000 over two years

Deadline: 03 Nov 2020

Small Research Pump Priming Grants

Purpose: Grants are awarded for pump priming projects. Requests for running costs to support established projects will be less favourably reviewed than those for pilot work that has the potential to facilitate applications for more substantial funding in the future. Research project submissions should the priority areas for research: Cancer research of demonstrable direct clinical relevance to the management of solid tumours. The application should also include a well-defined exit strategy (i.e. how the project will be taken forward).

Funder: Royal College of Surgeons of Edinburgh (RCSEd)
Applicant: Early Career and Emerging in Field
Amount: £10,000

Deadline: 04 Nov 2020

Pilot Award

Purpose: Pilot Awards support senior investigators who propose potentially transformative ideas that do not have extensive preliminary data but articulate a clear hypothesis and translational goals. Resources for such “high-risk, high-reward” projects are important to establish proof-of-concept, which may then leverage additional funding through more traditional avenues.

Funder: Melanoma Research Alliance (MRA)
Applicant: Mid-Career to Established in Field
Amount: $50,000/year over 2 years

Deadline: 04 Nov 2020

Established Investigators Academic-Industry Partnership Awards

Purpose: The Academic-Industry Partnership Award (for Established Investigators) is designed to enhance translational research by extending academic capabilities to clinical investigations and to facilitate interactions between the academic and industrial research sectors. These awards will be co-funded by MRA and an industry partner whose involvement is essential to the project. For the 2020-2021 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma.

Funder: Melanoma Research Alliance (MRA)
Applicant: Mid-Career to Established in Field
Amount: $125,000/year for 3 years

Deadline: 04 Nov 2020

Established Investigator Awards

Purpose: Established Investigator Awards support senior investigators with an established record of scientific productivity and accomplishment. For the 2020-2021 cycle, MRA seeks proposals in the following areas, which are focused on current unmet clinical needs in melanoma.

Funder: Melanoma Research Alliance (MRA)
Applicant: Mid-Career to Established in Field
Amount: $125,000/year for 3 years

Deadline: 04 Nov 2020

Pershing Square Sohn Prize for Young Investigators in Cancer Research

Purpose: The Pershing Square Sohn Prize for Young Investigators in Cancer Research provides New York area-based early-career scientists the freedom to take risks and pursue their boldest research at a stage when traditional funding is lacking. The Pershing Square Sohn Cancer Research Alliance (PSSCRA) is dedicated to accelerating cures for cancer by advancing the pursuit of innovative cancer research and by facilitating collaborations between the science and business communities. PSSCRA seeks to guide philanthropic funds to feed critical scientific discoveries, attracting like-minded investors to the cause of fighting cancer and creating a pipeline for early-stage biomedical investments.
Funder: Pershing Square Sohn Cancer Research Alliance
Applicant: Early Career and Emerging in Field
Amount: $200,000/year for up to 3 years

Letter of Intent Deadline: 09 Nov 2020

Technology Impact Award

Purpose: The Cancer Research Institute Technology Impact Award provides seed funding to be used to address the gap between technology development and clinical application of cancer immunotherapies. These grants aim to encourage collaboration between technology developers and clinical cancer immunologists and to generate the proof-of-principle of a novel platform technology in bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, or other relevant technologies that can enable clinician scientists to generate deeper insights into the mechanisms of action of effective or ineffective cancer immunotherapies. The most competitive applicants will address areas where technological innovation stands to benefit the field and cancer patients most, and that will ultimately lead to effective next generation cancer immunotherapies.

Funder: Cancer Research Institute (CRI)

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000 for up to 2 years

Letter of Intent Deadline: 15 Nov 2020

Deadline: 15 Mar 2020

PANCAN Career Development Award

Purpose: The Pancreatic Cancer Action Network Career Development Award represents an effort to encourage and support junior faculty to conduct pancreatic cancer research and establish successful career paths in this field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. Special consideration will be given to understudied areas in pancreatic cancer research.

Funder: Pancreatic Cancer Action Network (PANCAN)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $200,000 over 2 years

Deadline: 20 Nov 2020

St. Louis Ovarian Cancer Awareness Research Grant
Purpose: The Foundation gratefully acknowledges St. Louis Ovarian Cancer Awareness and Caring Together, Inc., of NY for their combined support of this grant. St. Louis Ovarian Cancer Awareness is committed to impacting ovarian cancer survivorship by promoting awareness of early warning signs and standards of care, funding ovarian cancer research, and supporting survivors.
Funder: Foundation for Women’s Cancer (FWC)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000

Deadline: 25 Nov 2020

Scientific Scholar Award
Purpose: The Rivkin Center Scientific Scholar Award is intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Research funding for ovarian cancer is comparatively low, which discourages talented laboratory scientists and physicians from directing their careers toward ovarian cancer. The Scientific Scholar Award provides the funds for the best and brightest minds to have an opportunity to begin a career in ovarian cancer research. The program will strive to support the scientific growth and academic success of awardees. The goal is to attract junior investigators as well as established investigators into ovarian cancer research and to develop their potential as leaders. The Scientific Scholar Award program will produce leaders in multiple areas of ovarian cancer research.
Funder: Marsha Rivkin Center for Ovarian Cancer Research
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $120,000 over 2 years

Deadline: 01 Dec 2020

Pilot Study Awards

Purpose: Investigators often struggle to find funding for innovative approaches to scientific questions because their new ideas may not yet be in the scientific mainstream. Each year we support multiple pilot studies to pave the way for new avenues of ovarian cancer research and to expand our understanding of the disease.
Funder: Marsha Rivkin Center for Ovarian Cancer Research
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $75,000 per year for two years

Deadline: 01 Dec 2020

SWOG Early Exploration and Development (SEED) Fund

Purpose: Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial-associated projects (translational medicine studies) within SWOG and the National Clinical Trials Network (NCTN). These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early-stage clinical trials), small, self-contained research projects, or development of research methodology/technology.

Funder: The Hope Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000 over 1 or 2 years

Deadline: 01 Dec 2020

Research Grants – General RFP

Purpose: The Desmoid Tumor Research Foundation, Inc. (“DTRF”) funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the country dedicated to facilitating and funding research for a cure for desmoid tumors. We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to present the results of their research at the annual September International DTRF Desmoid Tumor Research Workshop, and to make best efforts to attend the Workshop thereafter.

Funder: Desmoid Tumor Research Foundation (DTRF)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $65,000

Deadline: 01 Dec 2020

New Investigator Request for Proposals

Purpose: The purpose of this Request for Proposal is to fund early-stage research that will explore new approaches to advance the current scientific knowledge about desmoid tumors, resulting in the development of new treatment options and bringing us closer to our ultimate goal – a cure. Specifically, this RFP seeks applications from young investigators (at the rank of Associate Professor or below) who are new to desmoid tumor research and need seed funding to gather preliminary data to enable the applicant to apply for funding to support a more fully developed line of research in the future. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to present the results of their research at the annual September International DTRF Desmoid Tumor Research Workshop, and to make best efforts to attend the Workshop thereafter.

Funder: Desmoid Tumor Research Foundation (DTRF)
Applicant: Early Career and Emerging in Field
Amount: $30,000

Deadline: 01 Dec 2020

Scholar (Career Development) Award

Purpose: The Scholar (Career Development) Award is meant to help develop the independent research of highly qualified individuals still early in their careers. Recipients are called St. Baldrick’s Scholars.

Funder: St. Baldrick’s Foundation
Applicant: Early Career and Emerging in Field
Amount: $110,000/year for 2 years

Letter of Intent Deadline: 04 Dec 2020

PSC-CUNY Research Award Program

Purpose: Cycle 52 of the PSC-CUNY Research Award Program is now active. The Professional Staff Congress-City University of New York (PSC-CUNY) Research Award Program supports activities in the creative arts and in all academically relevant research in the areas of natural science, social science, and the humanities, including but not limited to research related to curriculum development, improvement in teaching, adaptation of standard educational techniques to special clientele, and the relationship between technical or occupational training and the liberal arts curriculum.

Funder: Professional Staff Congress-City University of New York (PSC-CUNY)
Applicant: Early Career and Emerging in Field
Amount: $3,500 – $12,000

Deadline: 01 Dec 2020

CORE Grants: AHNS/AAO-HNSF Translational Innovator Combined Award

Purpose: The purpose of this award is to support contemporary basic or clinical research focused on neoplastic disease of the head and neck for full time academic surgeons to promote novel translational research preferably with biomarker ideas. Research supported by this award should be specifically directed toward the pathogenesis, pathophysiology, diagnosis, prevention, or treatment of head and neck neoplastic disease, and may be either basic or clinical/translational in approach. While not specifically required, proposals which aim to introduce new knowledge and methodology from other disciplines to research in head and neck disease, or which demonstrate collaborative effort with members of other related disciplines are encouraged.

Funder: American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF)
Applicant: Early Career and Emerging in Field
Amount: $80,000 over 2 years

Letter of Intent Deadline: 15 Dec 2020

CISE Community Research Infrastructure (CCRI)

Purpose: The Computer and Information Science and Engineering (CISE) Community Research Infrastructure (CCRI) program drives discovery and learning in the core CISE disciplines of the three participating divisions [(Computing and Communication Foundations (CCF), Computer and Network Systems (CNS), and Information and Intelligent Systems (IIS)] by funding the creation and enhancement of world-class research infrastructure. This research infrastructure will specifically support diverse communities of CISE researchers pursuing focused research agendas in computer and information science and engineering. This support involves developing the accompanying user services and engagement needed to attract, nurture, and grow a robust research community that is actively involved in determining directions for the infrastructure as well as management of the infrastructure.

Funder: National Science Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000 – $5,000,000

Letter of Intent Deadline: 15 Dec 2020

AACR-Bristol Myers Squibb Midcareer Female Investigator Grant

Purpose: The AACR-Bristol Myers Squibb Midcareer Female Investigator Grant represents a joint effort to encourage and support mid-career female physician-scientists and researchers to conduct immuno-oncology research and to foster their career advancement toward becoming a senior investigator. Research projects may be translational and/or clinical in nature with a focus on immuno-oncology.

Funder: American Association for Cancer Research (AACR)
Applicant: Mid-Career to Established in Field / Female
Amount: $225,000 over 3 years

Deadline: 17 Dec 2020

Yamagiwa-Yoshida Memorial International Study Grants (YY)

Purpose: The YY Study Grants provide an important opportunity to advance cancer research through international collaboration. Their purpose is to enable individuals from any country to carry out cancer research projects abroad and including the opportunity to receive further training in research methods or techniques.

Funder: Union for International Cancer Control (UICC)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $10,000

Deadline: 31 Dec 2020

NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed)

Purpose: This funding opportunity announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for laboratory-based scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 04 Jan 2021

Mid-scale Research Infrastructure-1 (Mid-scale RI-1)

Purpose: NSF-supported science and engineering research increasingly relies on cutting-edge infrastructure. With its Major Research Instrumentation (MRI) program and Major Multi-user Facilities (Major Facilities) projects, NSF supports infrastructure projects at the lower and higher ends of infrastructure scales across science and engineering research disciplines. The Mid-scale Research Infrastructure Big Idea is intended to provide NSF with an agile, Foundation-wide process to fund experimental research capabilities in the mid-scale range between the MRI and Major Facilities thresholds.

Funder: National Science Foundation (NSF)

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field

Amount: $600,000 – $20,000,000

Preliminary Proposals Deadline: 07 Jan 2021

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (Collaborative U54 Clinical Trial Optional)

Purpose: This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $2,500,000/yr for up to 5 years

Deadline: 11 Jan 2021 

Collaborative Approaches to Engineer Biology for Cancer Applications (U01 Clinical Trial Not Allowed)

Purpose: This funding opportunity announcement invites applications to develop and apply innovative synthetic biology approaches to address challenges across the spectrum of cancer research. Projects will be required to apply a technology, based on an engineered biological system, to an important and well-defined cancer research question. Collaborative transdisciplinary teams are expected with PIs representing expertise in cancer research, engineering, and other disciplines relevant to synthetic biology.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $499,999/yr for 5 years

Deadline: 15 Jan 2021

Lila and Murray Gruber Memorial Cancer Research Award and Lectureship

Purpose: The purpose of this award is to encourage participation in cancer research and to provide a forum for the enrichment of knowledge of dermatologists in this important scientific field. At the discretion of the task force, the award may be divided between two worthy nominees.

Funder: American Academy of Dermatology (AAD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $10,000

Deadline: 15 Jan 2021

Major Research Instrumentation Program (MRI): Instrument Acquisition or Development

Purpose: The Major Research Instrumentation (MRI) Program serves to increase access to multi-user scientific and engineering instrumentation for research and research training in our Nation’s institutions of higher education and not-for-profit scientific/engineering research organizations. An MRI award supports the acquisition or development of a multi-user research instrument that is, in general, too costly and/or not appropriate for support through other NSF programs. MRI provides support to acquire critical research instrumentation without which advances in fundamental science and engineering research may not otherwise occur. MRI also provides support to develop next-generation research instruments that open new opportunities to advance the frontiers in science and engineering research. Additionally, an MRI award is expected to enhance research training of students who will become the next generation of instrument users, designers and builders.

Funder: National Science Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000 – $4,000,000

Deadline: 19 Jan 2021

Investigator-Initiated Research

Purpose: Our Investigator-Initiated Research Grant Program welcomes proposals for research addressing the effects of diet, nutrition, body composition and physical activity on cancer risk and outcomes. AICR funds research that focuses on the intersection of diet, weight, physical activity, and cancer risk.

Funder: American Institute for Cancer Research (AICR)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $225,000

Letter of Intent Deadline: 22 Jan 2021

Support of Competitive Research (SCORE) Research Advancement Award (SC1 Clinical Trial Not Allowed)

Purpose: The Research Advancement Award (SC1) is intended for established investigators who can demonstrate a need to augment their research skills and productivity in order to transition to non-SCORE sources of support in a maximum of eight years. Generally, these PD/PIs are seeking to improve the quality/quantity of preliminary data and/or publications to be able to succeed in acquiring non-SCORE research support.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $250,000/yr for up to 4 years

Deadline: 25 Jan 2021

Support of Competitive Research (SCORE) Pilot Project Award (SC2 Clinical Trial Not Allowed)

Purpose: The Pilot Project Award (SC2) allows junior investigators who are beginning an independent research career, i.e., in the early stages of an academic career and who have not had independent research support, to test a new idea or gather preliminary data to establish a new line of research. Guidance from productive, established, and well-funded U.S. scientist(s) in the proposed field of research is required. The advisor should be an established, NIH-funded investigator in the proposed research area and must have a track record of success in advising research scientists in the acquisition of external support and the maintenance of an independent research laboratory.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000/yr for 3 years

Deadline: 25 Jan 2021

Support of Competitive Research (SCORE) Research Continuance Award (SC3 Clinical Trial Not Allowed)

Purpose: The Research Continuance Award (SC3) allows investigators who already have conducted research and published to continue to engage in meritorious research projects of limited scope in a given biomedical area within the scope of the NIH mission. It is expected that the SC3 award will increase the PD/PI’s research productivity and peer-reviewed publications, thus allowing SC3 investigators to eventually transition to non-SCORE support.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $75,000/yr for up to 4 years

Deadline: 25 Jan 2021

National Cancer Institute Program Project Applications (P01 Clinical Trial Optional)

Purpose: With this funding opportunity announcement, the National Cancer Institute (NCI) invites applications for investigator-initiated Program Project (P01) applications. The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of project

Deadline: 25 Jan 2021

New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not Allowed)

Purpose: Through this Funding opportunity announcement, the National Cancer Institute (NCI) invites applications to support innovative scientific research in new prospective cohorts that addresses knowledge gaps in cancer etiology and carcinogenesis process with a focus on environmental exposures. Applicants are encouraged to use validated and reproducible innovative techniques to measure environmental exposures relevant to the proposed scientific research questions.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of project

Deadline: 29 Jan 2021

ILCF Young Investigator Awards

Purpose: Adequate research funding is key to furthering developments in lung cancer treatment. Through partnering with foundations, non-profits, corporations and individual donors, the International Lung Cancer Foundation (ILCF) provides multiple funding opportunities each year to facilitate scientific advances and save lives. For investigators who are ready to begin independent research studies/stand on your own two feet, ILCF offers numerous awards on an annual cycle, dependent on geographic region of applicant.

Funder: International Association for the Study of Lung Cancer (IASLC)
Applicant: Early Career and Emerging in Field
Amount: $50,000

Deadline: 31 Jan 2021

Young Investigator Award

Purpose: PSC Partners Seeking a Cure is delighted to provide a Young Investigator Award to promising researchers who are at the early stages of their research career and are interested in clinical, translational or basic research on Primary Sclerosing Cholangitis.

Funder: PSC Partners Seeking a Cure
Applicant: Early Career and Emerging in
Amount: $80,000 over 2 years

Deadline: 31 Jan 2021

Research Professor Grants

Purpose: The American Cancer Society offers a limited number of grants to investigators who have made seminal contributions that have changed the direction of basic cancer research. Funder: American Academy of Dermatology (AAD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $80,000

Letter of Intent Deadline: 01 Feb 2021

Research Grants

Purpose: The Sarcoma Foundation of America has developed a program to provide grants to investigators interested in translational science sarcoma research. Funding is available to cover equipment and supplies in support of research on the etiology, molecular biology, pathogenesis, diagnosis, and treatment of human sarcomas. In accordance with the mission of the Foundation, research involving the development of novel agents against sarcoma, or research that could potentially lead to the development of novel agents against sarcoma, is eligible for this funding.

Funder: Sarcoma Foundation of America (SFA)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000

Deadline: 01 Feb 2021

Improving Methods for Conducting Patient-Centered Outcomes Research

Purpose: With this PCORI Funding Announcement (PFA), PCORI aims to fund studies that address high-priority methodological gaps in patient-centered outcomes research (PCOR) and clinical comparative effectiveness research (CER). PCORI seeks to improve how massive amounts of data from a variety of sources can be: (1) appropriately analyzed and integrated into clinical care and health care delivery systems, and (2) facilitate population health models and social determinants of health analyses. Proposals should address mechanisms seeking to improve equitable, inclusive data collection and aggregation.

Funder: Patient-Centered Outcomes

Research Institute (PCORI)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $12,000,000 over 3 years

Letter of Intent Deadline: 02 Feb 2021

Hollis Brownstein Research Grants Program

Purpose: The Leukemia Research Foundation exclusively funds New Investigators – individuals beginning to establish their own laboratories that are no longer under the tutelage of a senior scientist mentor. It is difficult for them to get the level of funding they need at this critical point in their careers. The Leukemia Research Foundation is unique in the level of support it provides to highly promising scientists in this absolutely critical research niche. Providing one year grants to selected New Investigator researchers allows innovative scientists to act on their ideas, and try new procedures and experiments that will hopefully lead to significant breakthroughs.

Funder: Leukemia Research Foundation, Inc.
Applicant: Early Career and Emerging in Field
Amount: $100,000

Letter of Intent Deadline: 05 Feb 2021

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)

Purpose: The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. The special Interest is to encourage innovative health services research that can directly and demonstrably contribute to the improvement of minority health and/or the reduction of health disparities at the health care system-level as well as within clinical settings.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Feb 2021

Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional)

Purpose: This Funding Opportunity Announcement (FOA) invites applications for intervention research designed to support caregivers of adult cancer patients. Interventions supported by this FOA are intended to provide caregivers with care training, promote coping skills, and ultimately help them manage care. Outcomes of such interventions are expected to (1) optimize patient health care utilization, (2) improve caregiver well-being, and (3) improve patient physical health and psychosocial outcomes.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of project

Deadline: 05 Feb 2021

Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)

Purpose: The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 05 Feb 2021

Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

Purpose: This funding opportunity announcement encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 08 Feb 2021

NCI Mentored Research Scientist Development Award to Promote Diversity (K01 -Independent Clinical Trial Not Allowed)

Purpose: The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of “protected time” for intensive research career development under the guidance of an experienced mentor.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 12 Feb 2021

 

Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial Not Allowed)

Purpose: The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and “protected time” for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 12 Feb 2021

 

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

Purpose: The purpose of this funding opportunity announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 16 Feb 2021

 

Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based interventions, tools, policies, and guidelines. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of interventions that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. All applications must be within scope of the mission of one of the Institutes/Centers listed.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $50,000/yr for 2 years

Deadline: 16 Feb 2021

 

Using Information Technology to Support Systematic Screening and Treatment of Depression in Cancer (R21 Clinical Trial Optional)

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to: identify new, information technology (IT)-enabled delivery models that support systematic screening and treatment of depression in cancer patients; test the feasibility of implementing these new delivery models in a variety of oncology practice settings, especially those serving under-served populations; and test the effectiveness of the components of these new delivery models. The long-term goal of this FOA is to reduce the morbidity and mortality caused by depression in patients with cancer.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 16 Feb 2021

 

Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)

Purpose: This funding opportunity announcement (FOA) encourages grant applications from investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $275,000 over 2 years

Deadline: 18 Feb 2021

 

NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional)

Purpose: This funding opportunity announcement supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000 over 2 years

Deadline: 24 Feb 2021

 

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

Purpose: The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation’s research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation’s biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $300,000 over 3 years

Deadline: 25 Feb 2021

 

EHR Core Research (ECR): Building Capacity in STEM Education Research (ECR: BCSER)

Purpose: ECR’s Building Capacity for STEM Education Research (ECR: BCSER) solicitation supports projects that build individuals’ capacity to carry out high quality STEM education research that will enhance the nation’s STEM education enterprise and broaden the pool of researchers that can conduct fundamental research in STEM learning and learning environments, broadening participation in STEM fields, and STEM workforce development.

Funder: National Science Foundation (NSF)

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field

Amount: $600,000 – $20,000,000

Deadline: 26 Feb 2021

 

Agilent Early Career Professor Award

Purpose: The purpose of the Agilent Early Career Professor Award is to promote and encourage excellent research enabling measurements of importance to Agilent Technologies and the world, establish strong collaborative relationships between Agilent researchers and leading professors early in their career, and build the prominence of Agilent as a sponsor of university research. Alignment with the 2021 Focus: Contributions to the development of breakthrough solutions to understand or manage immunological responses to infection, autoimmunity or cancer.

Funder: Agilent Technologies
Applicant: Early Career and Emerging in Field
Amount: $100,000

Nomination Deadline: 28 Feb 2021

 

Translational Adult Glioma Grant Award

Purpose: The Ben & Catherine Ivy Foundation Emerging Adult Glioma Award provides grant support to investigators conducting high-impact, high-reward translational research for glioma. This award is intended to support projects designed to contribute to identifying therapies that will impact the survival of patients with brain cancer.

Funder: Ivy Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $600,000

Deadline: 01 Mar 2021

 

Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)

Purpose: This funding opportunity announcement (FOA) seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 04 Mar 2021

 

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)

Purpose: National Institutes of Health (NIH)

Funder: This funding opportunity announcement (FOA) calls for research on a broad range of scientific areas within NCI’s Division of Cancer Control and Populations Sciences’ (DCCPS) mission and portfolio, including but not limited to research in statistical and analytic methods, epidemiology and genomics, cancer survivorship, cancer-related behaviors, health care delivery, and implementation science.
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $250,000 over a maximum 5 years

Deadline: 08 Mar 2021

 

Breakthrough Award Levels 1 and 2

Purpose: Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. Potential impact of the research may be near-term or long-term, but it must move beyond a minor advancement and have the potential to lead to a new approach that is fundamentally better than interventions already approved or in clinical development.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $450,000 – 2,000,000

Letter of Intent Deadline: 11 Mar 2021

 

Innovator Award

Purpose: The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.  The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $7,000,000

Pre-Application Deadline: 12 Mar 2021

Advanced Scientific Research Grants

Purpose: The Eppley Foundation supports advanced, novel, scientific research by PhDs or MDs with an established record of publication in their specialties. Candidates with newly awarded doctorates occasionally, but rarely, meet the Foundation’s requirements for advanced research. Any applicant to the Foundation must be associated with a nonprofit organization with headquarters or a branch office in the US to process the funds.

Funder: Eppley Foundation for Research
Applicant: Mid-Career to Established in Field
Amount: $460,000

Deadline: 15 Mar 2021

 

Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)

Purpose: This funding opportunity announcement solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Research areas of interest include understanding differences and similarities between objective social isolatedness and loneliness, how complex biopsychosocial processes are regulated in the body, what occurs in response to dysregulation, and antecedent processes that influence responses to the trajectories of social relationships.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 17 Mar 2021

 

Mid-Career Enhancement Awards to Integrate Basic Behavioral, Biomedical, and/or Social Scientific Processes (K18 No Independent Clinical Trials)

Purpose: This Funding Opportunity Announcement (FOA) invites applications from investigators who strive to expand their research trajectories through the acquisition of new knowledge and skills in the areas of basic psychological processes, sociological processes, and/or biomedical pathways—expertise that is beyond and enhances their current areas of expertise. The program will support career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct independent research projects that more thoroughly investigate interrelationships among behavioral, biological, endocrine, epigenetic, immune, inflammatory, neurological, psychological, and/or social processes.

Funder: National Institutes of Health (NIH)
Applicant: Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 17 Mar 2021

 

Biomedical Research Facilities (C06 Clinical Trial Not Allowed)

Purpose: This Funding Opportunity Announcement (FOA) invites qualified academic institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and nonprofit private institutions of higher education. Applications from both research-intensive institutions and Institutions of Emerging Excellence in biomedical research from all geographic regions in the nation are strongly encouraged. NIH recognizes the importance of all institutions of higher learning in contributing to the nation’s research capacity. The goal of this FOA is to upgrade or create novel biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Targeted projects are the modernization of core facilities and the development of other infrastructure serving an institution-wide research community on a shared basis.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $8,000,000

Deadline: 17 Mar 2021

 

Early Career Investigator Award

Purpose: METAvivor funds research that specifically addresses the mechanistic understanding, diagnosis, and/or treatment of metastatic breast cancer. METAvivor funds research focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients. We do not fund research that that seeks to prevent or diagnose breast cancer metastasis, or that is focused on improving quality of life.

Funder: METAvivor
Applicant: Early Career and Emerging in Field
Amount: $100,000

Letter of Intent Deadline: 24 Mar 2021

 

Research Award

Purpose: METAvivor funds research that specifically addresses the mechanistic understanding, diagnosis, and/or treatment of metastatic breast cancer. METAvivor funds research focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients. We do not fund research that that seeks to prevent or diagnose breast cancer metastasis, or that is focused on improving quality of life.

Funder: METAvivor
Applicant: Mid-Career to Established in Field
Amount: $250,000 for up to 2 years

Letter of Intent Deadline: 26 Mar 2021

 

NSF Scholarships in Science, Technology, Engineering, and Mathematics (S-STEM)

Purpose: The program seeks to 1) increase the number of low-income academically talented students with demonstrated financial need obtaining degrees in S-STEM eligible disciplines and entering the workforce or graduate programs in STEM; 2) improve the education of future scientists, engineers, and technicians, with a focus on low-income academically talented students with demonstrated financial need; and 3) generate knowledge to advance understanding of how interventions or evidence-based curricular and co-curricular activities affect the success, retention, transfer, academic/career pathways, and graduation of low-income students in STEM.

Funder: National Science Foundation (NSF)

Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field

Amount: $650,000 – $5,000,000

Deadline: 31 Mar 2021

 

Cancer Grand Challenge Awards

Purpose: Cancer Grand Challenges are intended to transform cancer research. Therefore, we are looking for applications that reflect this ambition. We want to see proposals for bold, innovative solutions to the challenges we have set, and to see evidence that applicants have actively sought out new, perhaps unusual, collaborations that will bring fresh thinking to these currently intractable problems. Cancer Grand Challenges are not intended to fund research that would be fundable by other response-mode schemes and initiatives.

Funder: Cancer Research UK (CRUK)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $40,000 – $25,000,000

Questionnaire Deadline: 01 Apr 2021

 

Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01- Clinical Trial Not Allowed)

Purpose: The purpose of the initiative is to support multidisciplinary research to understand the underlying etiologic factors and mechanisms that contribute to population-level disparities in chronic liver diseases and liver cancer in the U.S.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 01 Apr 2021

 

Exceptional Project Grants

Purpose: Breast Cancer Alliance invites clinical doctors and research scientists, including post docs, at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique and innovative research.

Funder: Breast Cancer Alliance, Inc.
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $100,000

Letter of Intent Deadline: 01 Apr 2021

 

Investigator-Initiated Research Award

Purpose: The Ovarian Cancer Research Program Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $600,000-$800,000

Pre-Application Deadline: 01 Apr 2021

 

Proteogenomics Research Award

Purpose: The Ovarian Cancer Research Program Proteogenomics Research Award supports the use of proteomics and/or genomics to explore new concepts or theories in ovarian cancer.  The award is intended to support the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.  The proposed research question should be innovative and have the potential to make an impact on ovarian cancer.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $250,000 over 2 years

Pre-Application Deadline: 01 Apr 2021

 

Machine Learning in the Chemical Sciences and Engineering

Purpose: The Dreyfus program for Machine Learning in the Chemical Sciences and Engineering provides funding for innovative projects in any area of Machine Learning (ML) consistent with the Foundation’s broad objective to advance the chemical sciences and engineering. The Foundation anticipates that these projects will contribute new fundamental chemical insight and innovation in the field. The Foundation encourages proposals to significantly stimulate and accelerate the development of the use of ML and other related aspects of data science to the Chemical Sciences and Engineering.

Funder: Camille and Henry Dreyfus Foundation
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 08 Apr 2021

 

NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)

Purpose: The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the NIH’s mission and to the public health. A conference is defined as a symposium, seminar, workshop, or any other organized and formal meeting, whether conducted face-to-face or via the internet, where individuals assemble (or meet virtually) for the primary purpose to exchange technical information and views or explore or clarify a defined subject, problem, or area of knowledge, whether or not a published report results from such meeting. The NIH recognizes the value to members of the research community and all other interested parties in supporting such forums.

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: varies to reflect the needs of the project

Deadline: 12 Apr 2021

 

Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional)

Purpose: The goal of this program is to support collaborative translational research projects aligned with NIH efforts to enhance the translation of basic biological discoveries into clinical applications that improve health. It encourages high quality science demonstrating the potential to result in understanding an important disease process or lead to new therapeutic interventions, diagnostics, or prevention strategies within the research interests and priorities of the participating NIH Institutes/Centers (ICs).

Funder: National Institutes of Health (NIH)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $500,000/yr over 5 years

Deadline: 15 Apr 2021

DoD Lung Cancer, Career Development Award

Purpose: The FY21 LCRP Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,200,000

Deadline: 20 Apr 2021

 

DoD Lung Cancer, Concept Award

Purpose: The FY21 LCRP Concept Award supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project; instead, this award mechanism allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations by supporting high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge

of lung cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,920,000

Deadline: 20 Apr 2021

 

DoD Peer Reviewed Medical Research Program Investigator-Initiated Research Award

Purpose: The PRMRP Investigator-Initiated Research Award is intended to support studies that will make an important contribution toward research and/or patient care for a disease or condition related to at least one of the FY21 PRMRP Topic Areas. The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study.  These data may be unpublished or from the published literature.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field / Mid-Career to Established in Field
Amount: $1,600,000 – $2,000,000 over 4 years

Pre-Application Deadline: 28 Apr 2021

 

DoD Peer Reviewed Medical Research Program Discovery Award

Purpose: The intent of the PRMRP Discovery Award is to support innovative, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies, or applications. Studies supported by this award are expected to lay the groundwork for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a sound scientific rationale and study design.  Innovation is the most important review criterion.  Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities.

Funder: Department of Defense (DoD)
Applicant: Early Career and Emerging in Field
Amount: $200,000 over 2 years

Pre-Application Deadline: 29 Apr 2021